Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia

被引：0
|
作者：
Swaminathan, Mahesh
Przespolewski, Amanda
Griffiths, Elizabeth A.
Thompson, James E.
Elshoury, Amro
Walinski, Wendy
Wang, Eunice S.
机构：
[1] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
[2] Roswell Pk Comprehens Canc Ctr, Dept Med, Leukemia Serv, Buffalo, NY USA
[3] Roswell Pk Comprehens Canc Ctr, Clin Res Serv, Buffalo, NY USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-152947
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4426
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III study
    Pardee, Timothy S.
    Luther, Sanjeev
    Buyse, Marc
    Powell, Bayard L.
    Cortes, Jorge
    [J]. FUTURE ONCOLOGY, 2019, 15 (28) : 3197 - 3208
  • [2] A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia
    Pardee, Timothy S.
    Anderson, Rebecca G.
    Pladna, Kristin M.
    Isom, Scott
    Ghiraldeli, Lais P.
    Miller, Lance D.
    Chou, Jeff W.
    Jin, Guangxu
    Zhang, Wei
    Ellis, Leslie R.
    Berenzon, Dmitriy
    Howard, Dianna S.
    Hurd, David D.
    Manuel, Megan
    Dralle, Sarah
    Lyerly, Susan
    Powell, Bayard L.
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (09) : 2060 - 2073
  • [3] Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine
    Raanani, P
    Shpilberg, O
    Gillis, S
    Avigdor, A
    Hardan, I
    Berkowicz, M
    Sofer, O
    Lossos, I
    Chetrit, A
    Ben-Yehuda, D
    Bell-Bassat, I
    [J]. LEUKEMIA RESEARCH, 1999, 23 (08) : 695 - 700
  • [4] A Phase Ib Dose-Finding Study of Oral Panobinostat In Combination with Cytarabine (ara-C) and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia (AML)
    Krauter, Jurgen
    Schlenk, Richard F.
    Schaich, Markus
    Bouscary, Didier
    Dombret, Herve
    Winiger, Ivo J.
    Squier, Margaret
    Bengoudifa, Bourras-Rezki
    Ottmann, Oliver G.
    [J]. BLOOD, 2010, 116 (21) : 1356 - 1356
  • [5] A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia
    Griffiths, Elizabeth A.
    Brady, William E.
    Tan, Wei
    Vigil, Carlos E.
    Thompson, James E.
    Ford, Laurie A.
    Dickey, Noelle M.
    Bashaw, Heather L.
    Sperrazza, Jill
    Wetzler, Meir
    Wang, Eunice S.
    [J]. LEUKEMIA RESEARCH, 2016, 43 : 44 - 48
  • [6] A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia
    Christian, Sonia
    Arain, Saad
    Patel, Pritesh
    Khan, Irum
    Calip, Gregory S.
    Agrawal, Vaibhav
    Sweiss, Karen
    Griffin, Shawn
    Cahill, Kirk
    Konig, Heiko
    Esen, Aysenur
    Shergill, Ardaman
    Odenike, Olatoyosi
    Stock, Wendy
    Quigley, John G.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (08) : 937 - 943
  • [7] Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Zeidner, Joshua F.
    Vincent, Benjamin G.
    Ivanova, Anastasia
    Foster, Matthew
    Coombs, Catherine C.
    Jamieson, Katarzyna
    Van Deventer, Hendrik
    Scibilia, Richard
    Blanchard, Laura
    Frank, Cassiopeia
    Gallagher, Sean
    Matson, Melissa
    Pepin, Katherine
    Vaught, Lori
    Vogler, Nancy
    Gojo, Ivana
    Luznik, Leo
    Serody, Jonathan S.
    [J]. BLOOD, 2017, 130
  • [8] Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia
    Klisovic, Rebecca B.
    Blum, William
    Liu, Zhongfa
    Xie, Zhiliang
    Kefauver, Cheryl
    Huynh, Lenguyen
    Zwiebel, James A.
    Devine, Steven M.
    Byrd, John C.
    Grever, Michael R.
    Chan, Kenneth K.
    Marcucci, Guido
    [J]. LEUKEMIA & LYMPHOMA, 2014, 55 (06) : 1332 - 1336
  • [9] A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia
    Wang, Amy Y.
    Weiner, Howard
    Green, Margaret
    Chang, Hua
    Fulton, Noreen
    Larson, Richard A.
    Odenike, Olatoyosi
    Artz, Andrew S.
    Bishop, Michael R.
    Godley, Lucy A.
    Thirman, Michael J.
    Kosuri, Satyajit
    Churpek, Jane E.
    Curran, Emily
    Pettit, Kristen
    Stock, Wendy
    Liu, Hongtao
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11 : 4
  • [10] A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia
    Amy Y. Wang
    Howard Weiner
    Margaret Green
    Hua Chang
    Noreen Fulton
    Richard A. Larson
    Olatoyosi Odenike
    Andrew S. Artz
    Michael R. Bishop
    Lucy A. Godley
    Michael J. Thirman
    Satyajit Kosuri
    Jane E. Churpek
    Emily Curran
    Kristen Pettit
    Wendy Stock
    Hongtao Liu
    [J]. Journal of Hematology & Oncology, 11
12345